RSCF — Reflect Scientific Income Statement
0.000.00%
Last trade - 00:00
- $5.79m
- $4.45m
- $2.04m
- 67
- 17
- 31
- 32
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.55 | 1.61 | 2.79 | 2.81 | 2.04 |
Cost of Revenue | |||||
Gross Profit | 1.06 | 0.992 | 1.72 | 1.93 | 1.22 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1.8 | 1.8 | 2.14 | 1.88 | 1.95 |
Operating Profit | -0.249 | -0.195 | 0.651 | 0.939 | 0.09 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.25 | -0.196 | 0.66 | 0.939 | 0.09 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.25 | -0.196 | 0.66 | 0.939 | 0.089 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -0.25 | -0.196 | 0.66 | 0.939 | 0.089 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.25 | -0.196 | 0.66 | 0.939 | 0.089 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.003 | -0.002 | 0.008 | 0.01 | 0.001 |